Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $6.27M.
ENTERPRISE VALUE (EV)
$6.27M
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.16M
Enterprise Value (EV)
$6.27M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.16M | $6.27M |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.18M | $11.81M |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.20M | $8.61M |
| Alzamend Neuro Inc (ALZN)vs › | $5.25M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | $6.02M |
| Lunai Bioworks Inc. (LNAI)vs › | $5.30M | $3.56M |
| Xenetic Biosciences, Inc. (XBIO)vs › | $5.01M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.37M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.37M | $3.20M |
| Pulmatrix, Inc. (PULM)vs › | $5.41M | $3.24M |
Market Cap
$5.16M
Total Debt
$1.44M
Cash
$337655.00
Enterprise Value
$6.27M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
